BioRestorative Therapies, Inc.
BRTX · XNASCIK 1505497fmd_0VZ3498JVSREC0FKA5PRYBG45WServices · Services-Misc Health & Allied Services, NECTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2026, 65 periods
Latest annual · FY2025
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (16)
- Net income
- (14)
- Free cash flow
- (11)
Latest quarter · Q1 FY2026
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (3)
- Net income
- (2)
- Free cash flow
- (2)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +44.3%
- Revenue, 5 yearsFY2020 to FY2025
- +36.1%
- Net income, 5 yearsFY2020 to FY2025
- n/m
BioRestorative Therapies, Inc. (BRTX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $359,700 | $401,000 | -10.3% | 10-K 2026-03-26 · proof |
| Gross profit | $335,856 | $372,928 | -9.9% | 10-K 2026-03-26 · proof |
| Operating income | -$15.6 million | -$11.6 million | 10-K 2026-03-26 · proof | |
| Net income | -$14.2 million | -$9 million | 10-K 2026-03-26 · proof | |
| Cash from operating activities | -$10.8 million | -$8.2 million | 10-K 2026-03-26 · proof | |
| Free cash flow | -$10.9 million | -$8.3 million | 10-K 2026-03-26 · proof | |
| Total assets | $4.1 million | $12.3 million | -66.8% | 10-K 2026-03-26 · proof |
| Total liabilities | $3.7 million | $3.7 million | -0.7% | 10-K 2026-03-26 · proof |
| Cash and cash equivalents | $1.5 million | $547,890 | +175.8% | 10-K 2026-03-26 · proof |
- What was BioRestorative Therapies, Inc. (BRTX)'s revenue in fiscal 2025?
- BioRestorative Therapies, Inc. (BRTX) reported revenue of $359,700 for fiscal 2025 (the year ended Dec 31, 2025), against $401,000 the year before (-10.3%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was BioRestorative Therapies, Inc. (BRTX)'s gross profit in fiscal 2025?
- BioRestorative Therapies, Inc. (BRTX) reported gross profit of $335,856 for fiscal 2025 (the year ended Dec 31, 2025), against $372,928 the year before (-9.9%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was BioRestorative Therapies, Inc. (BRTX)'s operating income in fiscal 2025?
- BioRestorative Therapies, Inc. (BRTX) reported operating income of -$15.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$11.6 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was BioRestorative Therapies, Inc. (BRTX)'s net income in fiscal 2025?
- BioRestorative Therapies, Inc. (BRTX) reported net income of -$14.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$9 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was BioRestorative Therapies, Inc. (BRTX)'s cash from operating activities in fiscal 2025?
- BioRestorative Therapies, Inc. (BRTX) reported cash from operating activities of -$10.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$8.2 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What was BioRestorative Therapies, Inc. (BRTX)'s free cash flow in fiscal 2025?
- BioRestorative Therapies, Inc. (BRTX) reported free cash flow of -$10.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$8.3 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are BioRestorative Therapies, Inc. (BRTX)'s total assets?
- As of Dec 31, 2025, BioRestorative Therapies, Inc. (BRTX) reported total assets of $4.1 million, against $12.3 million a year earlier (-66.8%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are BioRestorative Therapies, Inc. (BRTX)'s total liabilities?
- As of Dec 31, 2025, BioRestorative Therapies, Inc. (BRTX) reported total liabilities of $3.7 million, against $3.7 million a year earlier (-0.7%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
- What are BioRestorative Therapies, Inc. (BRTX)'s cash and cash equivalents?
- As of Dec 31, 2025, BioRestorative Therapies, Inc. (BRTX) reported cash and cash equivalents of $1.5 million, against $547,890 a year earlier (+175.8%). Source: the 10-K filed with the SEC on Mar 26, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BRTX&period_type=annual&limit=5"Information only, not investment advice.